Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (Serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting

被引:250
作者
Qvist, P
Christgau, S
Pedersen, BJ
Schlemmer, A
Christiansen, C
机构
[1] Ctr Clin & Basic Res, DK-2750 Ballerup, Denmark
[2] Osteometer Biotech AS, Herlev, Denmark
关键词
bone markers; bone turnover; C-terminal telopeptide of type I collagen (sCTx); serum CTx; diurnal variation; circadian variation;
D O I
10.1016/S8756-3282(02)00791-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We examined the diurnal variation in serum concentration of C-terminal telopeptide of type I collagen (serum CrossLaps, sCTx) under various conditions. The studies included a total of 100 individuals. Blood samples were collected every 3 h over 27 h. sCTx levels varied over the 24 h with a maximum at about 05:00 in the morning and a minimum of about 14:00 in the afternoon. The variation had a magnitude of about +/-40% around the 24 h mean and was similar in premenopausal and early and late postmenopausal women with normal and low bone mass. Furthermore, it was not affected by 5 days of bed-rest, by absence of a normal diurnal variation in cortisol production, or by absence of a normal light cycle (blindness). Nasal salmon calcitonin, an antiresorptive drug used for treatment of osteoporosis, was not able to break the circadian pattern whether the treatment was administered in the morning or the evening. The only parameter that showed a pronounced influence on the circadian variation was fasting, which reduced the variation significantly to about one fourth. From a practical point of view the results of this study demonstrate that samples for sCTx should be taken in the fasting state.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 22 条
[1]   Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women [J].
Bjarnason, NH ;
Christiansen, C .
BONE, 2000, 26 (06) :561-569
[2]  
BOLLEN AM, 1995, J BONE MINER RES, V10, P1885
[3]  
BONDE M, 1994, CLIN CHEM, V40, P1944
[4]  
Christgau S, 2000, CLIN CHEM, V46, P431
[5]  
Christgau S, 1998, CLIN CHEM, V44, P2290
[6]   Three-year follow-up of the use of transdermal 17β-estradiol matrix patches for the prevention of bone loss in early postmenopausal women [J].
Delmas, PD ;
Pornel, B ;
Felsenberg, D ;
Stakkestad, JA ;
Radowicki, S ;
Garnero, P ;
Hardy, P ;
Dain, MP ;
Petitier, B .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 184 (02) :32-40
[7]  
Fledelius C, 1997, J BIOL CHEM, V272, P9755
[8]   Application of a new serum assay for type I collagen cross-linked N-telopeptides: Assessment of diurnal changes in bone turnover with and without alendronate treatment [J].
Gertz, BJ ;
Clemens, JD ;
Holland, SD ;
Yuan, W ;
Greenspan, S .
CALCIFIED TISSUE INTERNATIONAL, 1998, 63 (02) :102-106
[9]   Diurnal variation of bone mineral turnover in elderly men and women [J].
Greenspan, SL ;
DresnerPollak, R ;
Parker, RA ;
London, D ;
Ferguson, L .
CALCIFIED TISSUE INTERNATIONAL, 1997, 60 (05) :419-423
[10]  
HANSON DA, 1992, J BONE MINER RES, V7, P1251